TRINITY BIOTECH PLC |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.73 USD | +2.37% |
|
-1.14% | -19.35% |
Presentation Operator MessageOperator (Operator)Good morning and welcome to the Trinity Biotec...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Trinity Biotech PLC is an Ireland-based develops, acquires, manufactures and markets medical diagnostic systems, including both reagents and instrumentation for the clinical laboratory and point-of-care segments of the diagnostic market. The Company's products are used to detect autoimmune, infectious and sexually transmitted diseases, diabetes and disorders of the liver and intestine. Its segments include the Americas and Rest of World. It is a provider of raw materials to the life sciences and research industries globally. It also operates a licensed reference laboratory that specializes in diagnostics for autoimmune diseases. Its POC brands include Uni-Gold, Recombigen, MarDx, FlexTrans, Premier and Ultra. Its clinical laboratory brands include ImmuBlot, ImmuGlo, ImmuLisa, OTOblot and EZ. The Company manufactures kits for the detection of specialty and esoteric biomarkers of infectious diseases and other associated laboratory products.
Calendar
2024-08-19
- Q2 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| -19.35% | 16M | |
| -1.49% | 12.71B | |
| +0.13% | 8.37B | |
| -1.12% | 5.4B | |
| +20.81% | 5.27B | |
| -0.74% | 4.63B | |
| -54.77% | 3.13B | |
| +24.56% | 2.77B | |
| -8.47% | 2.25B | |
| -1.86% | 1.95B |
- Stock Market
- Equities
- TRIB Stock
- News Trinity Biotech plc
- Transcript : Trinity Biotech plc, Q4 2022 Earnings Call, Mar 23, 2023